JP2019216716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019216716A5 JP2019216716A5 JP2019120643A JP2019120643A JP2019216716A5 JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5 JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- biomarker
- cancer
- level
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000090 biomarker Substances 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013078 crystal Substances 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- ZXWQZGROTQMXME-KMPXOGLXSA-N 2-hydroxy-n-[(e)-3-hydroxy-1-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)\C=C\CCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-KMPXOGLXSA-N 0.000 claims 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100021069 E3 ubiquitin-protein ligase ZFP91 Human genes 0.000 claims 1
- 101000818429 Homo sapiens E3 ubiquitin-protein ligase ZFP91 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913003P | 2013-12-06 | 2013-12-06 | |
| US61/913,003 | 2013-12-06 | ||
| US201461947963P | 2014-03-04 | 2014-03-04 | |
| US61/947,963 | 2014-03-04 | ||
| US201461990621P | 2014-05-08 | 2014-05-08 | |
| US61/990,621 | 2014-05-08 | ||
| US201462061050P | 2014-10-07 | 2014-10-07 | |
| US62/061,050 | 2014-10-07 | ||
| US201462064413P | 2014-10-15 | 2014-10-15 | |
| US62/064,413 | 2014-10-15 | ||
| US201462077835P | 2014-11-10 | 2014-11-10 | |
| US62/077,835 | 2014-11-10 | ||
| US201462087111P | 2014-12-03 | 2014-12-03 | |
| US62/087,111 | 2014-12-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Division JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019216716A JP2019216716A (ja) | 2019-12-26 |
| JP2019216716A5 true JP2019216716A5 (enExample) | 2020-02-13 |
| JP7142612B2 JP7142612B2 (ja) | 2022-09-27 |
Family
ID=53274285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
| JP2019120643A Active JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160313300A1 (enExample) |
| EP (1) | EP3077548B1 (enExample) |
| JP (2) | JP6573611B2 (enExample) |
| KR (1) | KR102299801B1 (enExample) |
| AU (1) | AU2014360328B2 (enExample) |
| BR (1) | BR112016012795A2 (enExample) |
| CA (2) | CA3206268A1 (enExample) |
| EA (1) | EA201691144A1 (enExample) |
| ES (1) | ES2903155T3 (enExample) |
| IL (2) | IL278381B2 (enExample) |
| MX (1) | MX386337B (enExample) |
| PH (1) | PH12016501041A1 (enExample) |
| WO (1) | WO2015085172A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2420498T (lt) | 2006-09-26 | 2017-10-25 | Celgene Corporation | 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai |
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| EA026100B1 (ru) | 2011-03-11 | 2017-03-31 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CN106232831B (zh) | 2013-11-06 | 2021-02-26 | 美国卫生和人力服务部 | 通过表达谱分析对淋巴瘤类型进行亚型分类的方法 |
| BR112016012795A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| IL294449B2 (en) | 2015-03-31 | 2024-05-01 | Syros Pharmaceuticals Inc | Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US20170038387A1 (en) * | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP2018525991A (ja) * | 2015-08-12 | 2018-09-13 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| CA2999179A1 (en) | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017100259A1 (en) * | 2015-12-08 | 2017-06-15 | Icahn School Of Medicine At Mount Sinai | Pretransplant prediction of post-transplant acute rejection |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US11311540B2 (en) | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| BR112018070547A2 (pt) * | 2016-04-08 | 2019-02-12 | Syros Pharmaceuticals, Inc. | agonistas de rara para o tratamento de aml e mds |
| ES2859423T3 (es) | 2016-04-20 | 2021-10-04 | Us Health | Evaluación del linfoma de células del manto y procedimientos relacionados con el mismo |
| SG10201607303YA (en) * | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| JP7227131B2 (ja) | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ－ｔ細胞の投薬を決定するための方法 |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| US11266677B2 (en) * | 2017-03-10 | 2022-03-08 | Memorial Sloan Kettering Cancer Center | Methods for treatment or prevention of leukemia |
| CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
| US20210024997A1 (en) * | 2017-10-16 | 2021-01-28 | Massachusetts Institute Of Technology | Cell atlas of healthy and diseased tissues |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
| BR112020023756A2 (pt) * | 2018-05-23 | 2021-02-09 | Celgene Corporation | tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| FI3886875T3 (fi) | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| CN109583222A (zh) * | 2018-12-07 | 2019-04-05 | 浪潮(北京)电子信息产业有限公司 | 分布式文件系统元数据服务器回收客户端权限方法及装置 |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020231937A1 (en) * | 2019-05-10 | 2020-11-19 | University Of Massachusetts | Irf2 as a prognostic biomarker and target for augmenting immunotherapy |
| WO2021016079A2 (en) * | 2019-07-19 | 2021-01-28 | Pascal Biosciences (Us), Inc. | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |
| BR112022007417A2 (pt) * | 2019-10-21 | 2022-07-12 | Celgene Corp | Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona |
| WO2021102420A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Interferon signaling as a cancer biomarker |
| CN115315260A (zh) * | 2019-12-02 | 2022-11-08 | 新基公司 | 治疗癌症的疗法 |
| WO2021118353A1 (en) * | 2019-12-11 | 2021-06-17 | Erasmus University Medical Center Rotterdam | Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias |
| CN111187755B (zh) * | 2020-02-20 | 2021-10-22 | 中国人民解放军军事科学院军事医学研究院 | 抗tpd52单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 |
| AU2021413227A1 (en) | 2020-12-31 | 2023-07-13 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| KR20230138000A (ko) * | 2021-02-03 | 2023-10-05 | 쿠리스 인코퍼레이션 | 피메피노스타트 요법에 대한 바이오마커 |
| KR102629955B1 (ko) * | 2021-02-19 | 2024-01-25 | 가톨릭대학교 산학협력단 | Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물 |
| CN113025720B (zh) * | 2021-04-28 | 2022-12-27 | 深圳市人民医院 | 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用 |
| US20240245664A1 (en) * | 2021-09-08 | 2024-07-25 | The Curators Of The University Of Missouri | Methods of using usp15 inhibitors |
| US20250283174A1 (en) * | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| US20250381272A1 (en) | 2022-06-22 | 2025-12-18 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| EP4611798A1 (en) | 2022-11-02 | 2025-09-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025164957A1 (ko) * | 2024-01-31 | 2025-08-07 | 남부대학교산학협력단 | 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0631635B1 (en) | 1992-03-04 | 2001-09-12 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7504225B2 (en) | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| JP5523831B2 (ja) | 2006-08-30 | 2014-06-18 | セルジーン コーポレイション | ５−置換イソインドリン化合物 |
| CN101541977A (zh) * | 2006-09-19 | 2009-09-23 | 诺瓦提斯公司 | 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物 |
| AU2008247398B2 (en) * | 2007-05-03 | 2013-10-10 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| US20090148853A1 (en) | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
| WO2010017515A2 (en) | 2008-08-08 | 2010-02-11 | Integrated Diagnostics Inc. | Breast cancer specific markers and methods of use |
| MX361467B (es) | 2008-10-29 | 2018-12-06 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
| AU2010236606A1 (en) * | 2009-04-14 | 2011-11-03 | Merck Sharp & Dohme Corp. | Interferon-alfa sensitivity biomarkers |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| JP5660578B2 (ja) * | 2009-10-20 | 2015-01-28 | 国立大学法人東京工業大学 | サリドマイド標的因子を利用したスクリーニング方法 |
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| ES2436358T3 (es) | 2010-04-21 | 2013-12-30 | Puritan Medical Products Company, Llc | Material y dispositivo de recogida |
| US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| WO2012125405A2 (en) | 2011-03-11 | 2012-09-20 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| PT2683384E (pt) * | 2011-03-11 | 2016-03-11 | Celgene Corp | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
| MX353482B (es) * | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
| US20130042333A1 (en) | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| WO2013106686A1 (en) * | 2012-01-13 | 2013-07-18 | Celgene Corporation | Biomarkers for the treatment of hepatocellular carcinoma |
| CA3136093C (en) | 2012-06-29 | 2025-07-08 | Celgene Corporation | METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON |
| JP6347782B2 (ja) | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| AU2014254056B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
| WO2015077058A2 (en) * | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| WO2015085160A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
| BR112016012795A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides |
| US20170242014A1 (en) | 2014-10-13 | 2017-08-24 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP2018525991A (ja) | 2015-08-12 | 2018-09-13 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| CA2999179A1 (en) | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2014
- 2014-12-05 BR BR112016012795A patent/BR112016012795A2/pt not_active Application Discontinuation
- 2014-12-05 IL IL278381A patent/IL278381B2/en unknown
- 2014-12-05 US US15/101,869 patent/US20160313300A1/en not_active Abandoned
- 2014-12-05 JP JP2016536629A patent/JP6573611B2/ja active Active
- 2014-12-05 KR KR1020167016778A patent/KR102299801B1/ko active Active
- 2014-12-05 EA EA201691144A patent/EA201691144A1/ru unknown
- 2014-12-05 AU AU2014360328A patent/AU2014360328B2/en active Active
- 2014-12-05 ES ES14868331T patent/ES2903155T3/es active Active
- 2014-12-05 EP EP14868331.1A patent/EP3077548B1/en active Active
- 2014-12-05 CA CA3206268A patent/CA3206268A1/en active Pending
- 2014-12-05 WO PCT/US2014/068795 patent/WO2015085172A2/en not_active Ceased
- 2014-12-05 CA CA2932120A patent/CA2932120C/en active Active
- 2014-12-05 MX MX2016007239A patent/MX386337B/es unknown
-
2016
- 2016-06-01 IL IL245981A patent/IL245981B/en active IP Right Grant
- 2016-06-01 PH PH12016501041A patent/PH12016501041A1/en unknown
-
2018
- 2018-04-05 US US15/946,618 patent/US10996215B2/en active Active
-
2019
- 2019-06-28 JP JP2019120643A patent/JP7142612B2/ja active Active
-
2021
- 2021-04-01 US US17/220,377 patent/US20220003749A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019216716A5 (enExample) | ||
| IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| Riely et al. | EGFR: the paradigm of an oncogene-driven lung cancer | |
| JP2018535951A5 (enExample) | ||
| Momeni‐Boroujeni et al. | Uterine mesenchymal tumours: recent advances | |
| Nardi et al. | Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment | |
| Gainor et al. | Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer | |
| Chen et al. | Non-small-cell lung cancers: a heterogeneous set of diseases | |
| Evans et al. | A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors | |
| Neumann et al. | Mutational spectrum of adult T-ALL | |
| Hata et al. | The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics | |
| JP2019510746A5 (enExample) | ||
| JP2018512413A5 (enExample) | ||
| Waller | Imatinib mesylate | |
| CN104837491A (zh) | 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮治疗癌症的方法 | |
| Hechtman et al. | Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF | |
| London et al. | Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics | |
| RU2015115151A (ru) | Ингибитор ret | |
| JP2022071077A5 (enExample) | ||
| JP2017501400A5 (enExample) | ||
| JP2018536636A5 (enExample) | ||
| Aprile et al. | Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor | |
| JP2015504677A5 (enExample) | ||
| JP2017538104A5 (enExample) |